首页> 外文期刊>Pharmacology, Biochemistry and Behavior >Targeting the renin angiotensin system for the treatment of anxiety and depression
【24h】

Targeting the renin angiotensin system for the treatment of anxiety and depression

机译:针对肾素血管紧张素系统治疗焦虑和抑郁症

获取原文
获取原文并翻译 | 示例
           

摘要

Emotional disorders like anxiety and depression are responsible for considerable morbidity and mortality all over the world. Several antidepressant and anxiolytic medications are available for the treatment of anxiety and depression. However, a significant number of patients either do not respond to these medications or respond inadequately. Hence, there is a need to identify novel targets for the treatment of anxiety and depression. In this review we focus on the renin angiotensin system (RAS) as a potential target for the treatment of these disorders. We review work that has evaluated the effects of various compounds targeting the RAS on anxiety- and depression-like behaviors. Further, we suggest future work that must be carried out to fully exploit the RAS for the treatment of anxiety and depression. The RAS provides an attractive target for both the identification of novel anxiolytic and antidepressant medications and/or for enhancing the efficacy of currently available medications used for the treatment of anxiety and depression.
机译:焦虑和抑郁等情绪障碍是全世界相当大的发病率和死亡率的原因。有几种抗抑郁和抗焦虑药物可用于治疗焦虑和抑郁。然而,相当一部分患者要么对这些药物没有反应,要么反应不充分。因此,有必要确定治疗焦虑和抑郁的新靶点。在这篇综述中,我们将肾素-血管紧张素系统(RAS)作为治疗这些疾病的潜在靶点。我们回顾了评估各种靶向RAS的化合物对焦虑和抑郁样行为的影响的工作。此外,我们建议今后必须开展工作,充分利用RAS治疗焦虑和抑郁。RAS为识别新型抗焦虑和抗抑郁药物和/或增强目前用于治疗焦虑和抑郁的药物的疗效提供了一个有吸引力的靶点。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号